Barrett's Esophagus Clinical Trial
Official title:
Probe-based Confocal Laser Endomicroscopy in Accurate Histopathologic Diagnosis of Neoplastic Gastrointestinal Lesion
To assess diagnostic accuracy and clinical effectiveness including cost-effectiveness analysis of pCLE in patients after finishing the endoscopic treatment of BORN in detecting persistent/recurrent IM, recurrent neoplasia and buried glands.
Confocal laser endomicroscopy (CLE) has been developed to overcome the limitations of the
current endoscopic sampling techniques. CLE allows detailed examination of cellular
structures since it provides images very similar to images which a pathologist can see in the
microscope. At present, probe based CLE (pCLE) is the only available technology of
endomicroscopy. Before optical biopsy, a fluorescein is given intravenously and then
fluorescent light coming from a horizontal special focal plane is detected during pCLE of the
digestive system.
CLE provide real-time histopathological diagnosis and can lead to an immediate endoscopic
treatment in case of early esophageal and gastric neoplasia.
Patients after treatment of Barrett's esophagus related esophageal neoplasia (dysplasia or
early cancer) should be surveilled endoscopically with biopsies to rule out relapse of
Barrett's esophagus or neoplasia.
Project A - pCLE in the detection of esophageal and gastric lesions:
We plan to investigate the diagnostic accuracy of pCLE (compared to standard histopathology)
in patients with endoscopically diagnosed early esophageal and gastric lesions.
Project B - pCLE in the detection of persistent/recurrent intestinal metaplasia/dysplasia in
patients after endoscopic treatment of BORN:
Investigators plan to perform a prospective cross-over study comparing the diagnostic
accuracy and sensitivity of pCLE with standard biopsies in patients after completed
endoscopic treatment of BORN. Surveillance endoscopies are focused on detection of
persistent/recurrent IM or dysplasia (ev. neoplasia). BORN is defined as low-grade dysplasia
(confirmed by a specialized esophageal pathologist) or as high grade dysplasia or early
adenocarcinoma. Investigators will also examine the ability of pCLE to detect buried glands
after radiofrequency ablation.
Methods:
Project A:
Patients referred to our department with a suspect and endoscopically visible lesion in the
esophagus or stomach will undergo pCLE during a standard upper GI endoscopy with pCLE. After
a real-time diagnosis (made by the endoscopist), the standard tissue sampling (biopsies,
endoscopic resection or dissection) followed by a standard histopathological tissue
assessment will follow.
Project B:
During one of surveillance endoscopies in patients after finishing the endoscopic treatment
of BORN (interval depends on baseline diagnosis), pCLE will be performed in the cardia,
neo-Z-line, esophagus body and visible lesions, and images will be stored. Thereafter,
standard biopsies will be taken and sent for histopathological analysis.
For optical biopsy, endoscopist (real time) and two expert pathologists will independently
blindly evaluate each "optical specimen". The standard biopsy specimen will be assessed
independently by a pathologist not assessing the optical biopsy. Results of optical biopsy
will be compared with results of standard biopsy.
Main hypothesis:
Project A:
pCLE is not inferior to standard biopsy (or resection) specimen in histopathological
diagnosing of esophageal/gastric lesions.
Project B:
pCLE is not inferior compared to standard biopsies in detecting persistent/recurrent IM,
recurrent neoplasia and buried glands.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02864043 -
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
|
N/A | |
Recruiting |
NCT02018367 -
Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT01572987 -
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
|
N/A | |
Terminated |
NCT01976351 -
Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus
|
N/A | |
Terminated |
NCT00526786 -
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
|
Phase 4 | |
Completed |
NCT01401699 -
Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
|
N/A | |
Completed |
NCT02106910 -
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy
|
N/A | |
Suspended |
NCT01580631 -
Narrow Band Imaging Project on Barrett's Esophagus
|
||
Completed |
NCT01439633 -
Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus
|
N/A | |
Completed |
NCT02879721 -
Expression and Function of the Renin-Angiotensin System in the Esophagus
|
Phase 0 | |
Completed |
NCT01439594 -
Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation
|
N/A | |
Completed |
NCT01281618 -
Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus
|
N/A | |
Completed |
NCT00586872 -
Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus
|
||
Completed |
NCT00844077 -
Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus
|
N/A | |
Completed |
NCT00588575 -
Ramanspectroscopy in Barrett's Esophagus
|
||
Recruiting |
NCT00288119 -
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
|
||
Completed |
NCT03813381 -
CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO).
|
N/A | |
Completed |
NCT02579460 -
Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition
|
N/A | |
Not yet recruiting |
NCT02033070 -
Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System
|
N/A | |
Completed |
NCT01961778 -
Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma
|
N/A |